重症哮喘靶向治疗的研究进展

支气管哮喘(简称哮喘)是一种慢性气道炎症性疾病,具有明显的异质性和复杂的病理生理表现.我国成人的哮喘患病率为1.24%,其中重症哮喘占5.99%.重症哮喘表现为控制水平差,是哮喘致残、致死的主要原因,临床治疗棘手.近年来,针对辅助T细胞(helper T cell,Th)2和Th17表型的生物靶向治疗药物成为哮喘新药开发的热点之一.生物靶向治疗药物为重症哮喘患者带来了新的希望.现就重症哮喘靶向治疗的研究现状进行综述,以期为临床医师治疗重症哮喘提供参考.

Research progress of the targeted therapy in severe asthma

Bronchial asthma(asthma)is a chronic airway inflammatory disease with obvious heterogeneity and complex pathophysiological manifestations.The prevalence of asthma in Chinese adults is 1.24%,of which severe asthma accounts for 5.99%.Severe asthma manifests as poor control which is the main cause of disability and death of asthma.Clinical treatment of severe asthma is tricky.In recent years,bio-targeted therapeutics targeting at the helper T cell(Th)2 and Th17 phenotypes have become one of the hot spots in the development of new asthma drugs.Bio-targeted therapeutics may be a new hope to patients with severe asthma.This review summarizes the research status of targeted therapy for severe asthma,hoping to provide reference for clinicians to treat severe asthma.